Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer
Conditions
Keywords
anaplastic lymphoma kinase, ALK-rearranged lung cancer, non-small cell lung cancer
Brief summary
The primary purpose of the study is to estimate the maximum tolerated dose of the combination of LDK378 and AUY922. This study will assess the safety, tolerability, pharmacokinetics and preliminary evidence of anti-tumor activity of the combination of LDK378 and AUY922 in ALK-rearranged non-small cell lung cancer.
Interventions
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* locally advanced or metastatic NSCLC that has progressed during or following therapy with an ALK inhibitor * tumor must carry an ALK rearrangement in 15% or more of tumor cells as measured by FISH * disease that can be evaluated by RECIST v1.1 and measurable disease
Exclusion criteria
* central nervous system (CNS) metastases that are symptomatic or require increasing steroids or CNS-directed therapy to control CNS disease * history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis * clinically significant cardiac dysfunction * inadequate end organ function as defined by specified laboratory values * use of medications known to be strong inhibitors or inducters of CYP3A4/5 that cannot be discontinued at least 1 week prior to start of treatment * use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be discontinued at least 1 week prior to start of treatment * clinically significant, uncontrolled impaired gastrointestinal function or GI disease * prior treatment with a HSP90 inhibitor * radiotherapy to lung within 4 weeks prior to the first dose of study treatment or patients who have not recovered from radiotherapy-related toxicities * pregnant or nursing women * history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence rate of Dose Limiting Toxicities (DLT) | up to day 28 after the patient's first dose | cycle = within the first 28 days of patient's first dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | 30 months | Assess the anti-tumor activity of LDK378 and AUY922 per RECIST 1.1 |
| Duration of Response (DoR) | 30 months | Assess the anti-tumor activity of LDK378 and AUY922 |
| Number of patients with adverse events | 30 months | Characterize the safety and tolerability of LDK378 and AUY922 in patients |
| Changes in laboratory values | 30 months | Characterize the safety and tolerability of LDK378 and AUY922 in patients |
| Assessments of electrocardiograms | 30 months | Characterize the safety and tolerability of LDK378 and AUY922 in patients |
| Assessments of dose interruptions, reductions, and dose intensity | 30 months | Characterize the safety and tolerability of LDK378 and AUY922 in patients |
| Plasma PK parameter of LDK378 and AUY922: Tmax | 30 months | Characterize single and multiple dose PK of LDK378 and AUY922 in patients |
| Time to Response (TTR) | 30 months | Assess the anti-tumor activity of LDK378 and AUY922 |
| Number of patients with serious adverse events | 30 months | Characterize the safety and tolerability of LDK378 and AUY922 in patients |
| Plasma PK parameter of LDK378 and AUY922: Cmax | 30 months | Characterize single and multiple dose PK of LDK378 and AUY922 in patients |
| Plasma PK parameter of LDK378 and AUY922: AUClast | 30 months | Characterize single and multiple dose PK of LDK378 and AUY922 in patients |
| Plasma PK parameter of LDK378 and AUY922: AUCtau | 30 months | Characterize single and multiple dose PK of LDK378 and AUY922 in patients |
| Plasma PK parameter of LDK378 and AUY922: Cmin | 30 months | Characterize single and multiple dose PK of LDK378 and AUY922 in patients |
| Plasma PK parameter of LDK378 and AUY922: Racc | 30 months | Characterize single and multiple dose PK of LDK378 and AUY922 in patients |
| Overall response rate (ORR) | 30 months | Assess the anti-tumor activity of LDK378 and AUY922 |
Countries
Australia, Italy, Singapore, Spain, United States
Outcome results
None listed